Ausgabe 2/2017
Inhalt (13 Artikel)
Management of Chronic Hepatitis B in Children
Danielle Wendel, Karen F. Murray
Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection
Mohit Mittal, Ke-Qin Hu
Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B Infection
Anthony W.H. Chan, Grace L.H. Wong, Vincent W.S. Wong
Ethnic Disparities in Chronic Hepatitis B Infection: African Americans and Hispanic Americans
Kimberly A. Forde
Autoimmune Hepatitis: When Is It Safe to Stop Therapy, or Withhold Therapy Altogether?
Christina Weiler-Normann, Johannes Hartl, Ansgar W. Lohse
Why Doesn’t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?
Antonio Molinaro, Hanns-Ulrich Marschall
Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?
Roger W Chapman, Kate D. Williamson
The Causes and Clinical Spectrum of Drug-Induced Cholestatic Liver Injury
Lara Dakhoul, Raj Vuppalanchi
Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?
Hager F. Ahmed Mohammed, Lewis R. Roberts
Multidisciplinary Team Management of Patients with Hepatocellular Carcinoma
Caitlin A. Hester, Ali A. Mokdad, Adam C. Yopp
Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?
Hannes Hagström
Portal Vein Thrombosis and Cirrhosis: The Role of Anticoagulation
Andrea Mancuso
Biomarkers and Liver Disease: Can We Predict Decompensation with suPAR?
Alexander Koch, Frank Tacke